02 May 2022 11:31 reads Source: China Youth Daily comments
On May 1, the first dose of inactivated vaccine against Omicron variant strain (hereinafter referred to as Ao strain), which was developed by Beijing Institute of Biological Products of China National Pharmaceutical Group, was officially completed in Hangzhou City, Zhejiang Province, for clinical study. This is the world's first inactivated neo-coronavirus vaccine for the Omicron variant strain to enter clinical trials.
This clinical study of an inactivated vaccine against Austrian strain neocoronavirus will be a non-randomized, open, externally controlled study.
The recent outbreak of neocrown pneumonia caused by Omicron variant strain in many places in China is characterized by high infectiousness, short incubation period, short transmission time and great difficulty in prevention and control. On December 9, 2021, China Biotechnology promptly started the development of a vaccine against the Omicron variant and obtained the clinical trial approval from the State Drug Administration on April 26, 2022. After obtaining the clinical approval, Shulan (Hangzhou) Hospital National Drug Clinical Trial Facility immediately carried out the preparatory work before the start of the project, and completed the review of the drug clinical trial ethics committee to obtain the ethical approval in the shortest possible time, and the clinical study was officially launched on May 1.
The vaccine, which requires two doses, will evaluate the safety and immunogenicity of the Omicron variant vaccine in people aged 18 years and older who have not been vaccinated against Neovirus. Upon approval of the data from this clinical study, the vaccine will be available directly to a blanket population that has not been vaccinated with Neocrown.
Academicians Li Lanjuan and Zheng Shusen of the Chinese Academy of Engineering, Yang Xiaoming, Chairman of China Biotechnology Corporation, and Zhang Yuntao, Vice President and Chief Scientist, attended the kick-off meeting online and delivered speeches.
Responsible Editor: ugmbbc